GlassScriptPhysician profile
Mark C Goldberg
NPI 1114914389
$3,486.41
in general payments reported to CMS, 2019-2025
31 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $206 · 2021: $461 · 2022: $405 · 2023: $794 · 2024: $702 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $849.65 | 2019-2025 | |
| Amgen INC. | $498.97 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $281.60 | 2019-2022 | |
| Boston Scientific Corporation | $201.59 | 2020-2025 | Cds - Mct/Cem Monitoring |
| Pfizer INC. | $187.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $166.35 | 2021-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $146.55 | 2023-2025 | Barostim Neo System |
| Amarin Pharma, INC. | $142.44 | 2019-2022 | |
| Heartflow, INC. | $127.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.05 | 2021-2023 | Verquvo |
| Baxter Healthcare | $85.35 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $67.26 | 2019-2022 | |
| Atricure, INC. | $67.17 | 2023 | |
| Sanofi-Aventis U.S. LLC | $50.73 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.23 | 2023-2025 | Cardiomems, Aveir |
| Kiniksa Pharmaceuticals International, Plc | $48.14 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $47.59 | 2023-2024 | Edarbi, Edarbi |
| Novo Nordisk INC | $37.69 | 2024 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $29.86 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $29.56 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.53 | 2023 | Lifevest |
| Impulse Dynamics (USA) INC. | $26.25 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $19.31 | 2023 | Inpefa |
| Philips North America LLC | $18.40 | 2023 | |
| Bridgebio Pharma, INC. | $18.27 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $17.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.35 | 2023 | Jardiance |
| Cleerly, INC. | $14.79 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Bardy Diagnostics, INC. | $12.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.